LAVA-1223

Seagen, amid deal rumors, spends $50M on a dual-targeting cancer drug
BioPharma Dive
Mon, 09/26/22 - 11:20 pm
Seagen
Merck
Lava Therapeutics
bispecific antibodies
LAVA-1223